Mostrar el registro sencillo del ítem
resumen
Resumen
Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the
[ver mas...]
dc.contributor.author | Alkayyal, Almohanad A. | |
dc.contributor.author | Ajina, Reham | |
dc.contributor.author | Cacciabue, Marco Polo Domingo | |
dc.contributor.author | Alkayyal, Aaesha A. | |
dc.contributor.author | Saeedi, Nizar H. | |
dc.contributor.author | Hussain Alshehry, Taofik | |
dc.contributor.author | Kaboha, Feras | |
dc.contributor.author | Alotaibi, Mohammed A. | |
dc.contributor.author | Zaidan, Nada | |
dc.contributor.author | Shah, Khalid | |
dc.contributor.author | Alroqi, Fayhan | |
dc.contributor.author | Bakur Mahmoud, Ahmad | |
dc.date.accessioned | 2023-09-15T10:32:33Z | |
dc.date.available | 2023-09-15T10:32:33Z | |
dc.date.issued | 2023-01 | |
dc.identifier.issn | 1664-3224 | |
dc.identifier.other | https://doi.org/10.3389/fimmu.2023.1082191 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12123/15220 | |
dc.identifier.uri | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1082191/full | |
dc.description.abstract | Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent. | eng |
dc.format | application/pdf | es_AR |
dc.language.iso | eng | es_AR |
dc.publisher | Frontiers Media | es_AR |
dc.rights | info:eu-repo/semantics/openAccess | es_AR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | es_AR |
dc.source | Frontiers in Immunology 14 : 1082191 (Enero 2023) | es_AR |
dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 | eng |
dc.subject | Coronavirus del Síndrome Respiratorio Agudo Arave 2 | es_AR |
dc.subject | Oncology | eng |
dc.subject | Oncología | es_AR |
dc.subject | Melanoma | eng |
dc.subject | Vesicular Stomatitis Virus | eng |
dc.subject | Virus de la Estomatitis Vesicular | es_AR |
dc.subject.other | SARS-CoV-2 | es_AR |
dc.subject.other | Virotherapy | eng |
dc.subject.other | Viroterapia | es_AR |
dc.subject.other | Anticancer Agent | eng |
dc.subject.other | Agente Anticancerígeno | es_AR |
dc.title | SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus | es_AR |
dc.type | info:ar-repo/semantics/artículo | es_AR |
dc.type | info:eu-repo/semantics/article | es_AR |
dc.type | info:eu-repo/semantics/publishedVersion | es_AR |
dc.rights.license | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) | es_AR |
dc.description.origen | Instituto de Biotecnología | es_AR |
dc.description.fil | Fil: Alkayyal, Almohanad A. University of Tabuk. Faculty of Applied Medical Sciences. Department of Medical Laboratory Technology; Arabia Saudita | es_AR |
dc.description.fil | Fil: Alkayyal, Almohanad A. King Abdullah International Medical Research Center. Immunology Research Program; Arabia Saudita | es_AR |
dc.description.fil | Fil: Ajina, Reham. King Abdullah International Medical Research Center. Immunology Research Program; Arabia Saudita | es_AR |
dc.description.fil | Fil: Ajina, Reham. King Saud bin Abdulaziz University for Health Sciences. College of Applied Medical Sciences. Department of Clinical Laboratory Sciences; Arabia Saudita | es_AR |
dc.description.fil | Fil: Cacciabue, Marco Polo Domingo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina | es_AR |
dc.description.fil | Fil: Cacciabue, Marco Polo Domingo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | es_AR |
dc.description.fil | Fil: Cacciabue, Marco Polo Domingo. Universidad Nacional de Luján. Departamento de Ciencias Básicas; Argentina | es_AR |
dc.description.fil | Fil: Alkayyal, Aaesha A. Taibah University. College of Medicine; Arabia Saudita | es_AR |
dc.description.fil | Fil: Saeedi, Nizar H. University of Tabuk. Faculty of Applied Medical Sciences. Department of Medical Laboratory Technology; Arabia Saudita | es_AR |
dc.description.fil | Fil: Hussain Alshehry, Taofik. Ministry of National Guard Health Affairs. King Saud University for Health Sciences. King Abdullah International Medical Research Centre; Arabia Saudita | es_AR |
dc.description.fil | Fil: Kaboha, Feras. Ministry of National Guard Health Affairs. King Saud University for Health Sciences. King Abdullah International Medical Research Centre; Arabia Saudita | es_AR |
dc.description.fil | Fil: Alotaibi, Mohammed A. University of Tabuk. Faculty of Applied Medical Sciences. Department of Medical Laboratory Technology; Arabia Saudita | es_AR |
dc.description.fil | Fil: Alotaibi, Mohammed A. Ministry of National Guard Health Affairs. King Saud University for Health Sciences. King Abdullah International Medical Research Centre; Arabia Saudita | es_AR |
dc.description.fil | Fil: Zaidan, Nada. King Abdulaziz City for Science and Technology. Joint Centers of Excellence Program. 8King Abdulaziz City for Science and Technology-Brigham and Women's Hospital (KACST-BWH) Centre of Excellence for Biomedicine; Arabia Saudita | es_AR |
dc.description.fil | Fil: Shah, Khalid. Harvard Medical School. Brigham and Women’s Hospital. Center for Stem Cell and Translational Immunotherapy (CSTI); Estados Unidos | es_AR |
dc.description.fil | Fil: Shah, Khalid. Harvard Medical School. Brigham and Women’s Hospital. Department of Neurosurgery; Estados Unidos | es_AR |
dc.description.fil | Fil: Shah, Khalid. Harvard University. Harvard Stem Cell Institute; Estados Unidos | es_AR |
dc.description.fil | Fil: Alroqi, Fayhan. King Abdullah International Medical Research Center. Immunology Research Program; Arabia Saudita | es_AR |
dc.description.fil | Fil: Alroqi, Fayhan. Ministry of the National Guard. Department of Immunology; Arabia Saudita | es_AR |
dc.description.fil | Fil: Alroqi, Fayhan. King Saud bin Abdulaziz University for Health Sciences. Faculty of Medicine; Arabia Saudita | es_AR |
dc.description.fil | Fil: Bakur Mahmoud, Ahmad. Taibah University. College of Applied Medical Sciences; Arabia Saudita | es_AR |
dc.description.fil | Fil: Bakur Mahmoud, Ahmad. Taibah University. Strategic Research and Innovation Laboratories; Arabia Saudita | es_AR |
dc.description.fil | Fil: Bakur Mahmoud, Ahmad. King Abdullah International Medical Research Center. Immunology Research Program; Arabia Saudita | es_AR |
dc.subtype | cientifico |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
common
-
Artículos científicos [374]